Advertisement

Topics

Alexion's Managed Access Agreement Only Partially Quashes Strensiq Cost Concerns

11:53 EDT 22 Sep 2016 | SCRIP

Alexion has only managed to convince NICE to recommend Strensiq for treatment in a limited patient population with pediatric-onset hypophosphatasia...

      

Related Stories

 

Original Article: Alexion's Managed Access Agreement Only Partially Quashes Strensiq Cost Concerns

NEXT ARTICLE

More From BioPortfolio on "Alexion's Managed Access Agreement Only Partially Quashes Strensiq Cost Concerns"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...